Global Firms Can Now Buy A Controlling Stake In Indian Companies, But The Debate Is Not Over
This article was originally published in PharmAsia News
A truce between government departments was reached on the issue of foreign direct investments in the pharmaceutical industry. In the new setting, the “non-compete” clause will be removed lending flexibility to the seller to start up a competing enterprise.
You may also be interested in...
MUMBAI - The Indian government has decided to route all foreign direct investments in existing Indian companies via the Foreign Investment Promotion Board, a surprising move that could have far-reaching implications on big ticket M&As in the country's pharmaceutical industry
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.